PPP2R2C

Summary

PPP2R2C (protein phosphatase 2 regulatory subunit Bgamma, HGNC:9306) is a protein-coding gene on chromosome 4p16.1, encoding Serine/threonine-protein phosphatase 2A 55 kDa regulatory subunit B gamma isoform (Q9Y2T4). The B regulatory subunit might modulate substrate selectivity and catalytic activity, and might also direct the localization of the catalytic enzyme to a particular subcellular compartment.

The product of this gene belongs to the phosphatase 2 regulatory subunit B family. Protein phosphatase 2 is one of the four major Ser/Thr phosphatases, and it is implicated in the negative control of cell growth and division. It consists of a common heteromeric core enzyme, which is composed of a catalytic subunit and a constant regulatory subunit, that associates with a variety of regulatory subunits. The B regulatory subunit might modulate substrate selectivity and catalytic activity. This gene encodes a gamma isoform of the regulatory subunit B55 subfamily. Alternatively spliced transcript variants encoding different isoforms have been identified.

Source: NCBI Gene 5522 — RefSeq curated summary.

At a glance

• GWAS associations: 5
• Clinical variants (ClinVar): 53 total
• MANE Select transcript: NM_020416

Identifiers

Gene identifiers

Field	Value
HGNC ID	HGNC:9306
Approved symbol	PPP2R2C
Name	protein phosphatase 2 regulatory subunit Bgamma
Location	4p16.1
Locus type	gene with protein product
Status	Approved
Aliases	PR52, IMYPNO, MGC33570, PR55G, B55gamma
Ensembl gene	ENSG00000074211
Ensembl biotype	protein_coding
OMIM	605997
Entrez	5522

Gene structure

Transcript identifiers

Ensembl transcripts: 9 — 5 protein_coding, 2 protein_coding_CDS_not_defined, 1 nonsense_mediated_decay, 1 retained_intron

ENST00000314348, ENST00000335585, ENST00000382599, ENST00000506140, ENST00000507028, ENST00000507294, ENST00000509917, ENST00000513943, ENST00000515571

RefSeq mRNA: 6 — MANE Select: NM_020416 NM_001206994, NM_001206995, NM_001206996, NM_001363388, NM_020416, NM_181876

CCDS: CCDS3387, CCDS3388, CCDS56304, CCDS56305

Canonical transcript exons

ENST00000382599 — 9 exons

Exon	Start	End
ENSE00000701041	6329262	6329353
ENSE00000701114	6333562	6333731
ENSE00001492745	6472160	6472614
ENSE00002084339	6320581	6323593
ENSE00003504503	6347846	6348010
ENSE00003533758	6375819	6375931
ENSE00003576459	6378407	6378572
ENSE00003614075	6372523	6372700
ENSE00003636815	6380997	6381094

Expression profiles

Bgee: expression breadth ubiquitous, 208 present calls, max score 99.07.

FANTOM5 (CAGE): breadth broad, TPM avg 7.8880 / max 262.1373, expressed in 517 samples.

FANTOM5 promoters (22 alternative TSS)

Promoter ID	TPM avg	Samples expressed
51251	4.1049	419
51249	1.1469	281
51261	0.5866	112
51248	0.5712	135
51247	0.2112	78
51253	0.1873	62
51262	0.1784	63
51246	0.1709	92
51254	0.1503	57
51252	0.1409	81

Top tissues by expression

253 total, by Bgee expression score (0-100, higher = more expressed):

Tissue	Anatomy ID	Expression score	Quality
middle temporal gyrus	UBERON:0002771	99.07	gold quality
Brodmann (1909) area 46	UBERON:0006483	98.87	gold quality
superior frontal gyrus	UBERON:0002661	98.61	gold quality
parietal lobe	UBERON:0001872	98.57	gold quality
postcentral gyrus	UBERON:0002581	98.55	gold quality
occipital lobe	UBERON:0002021	98.30	gold quality
Brodmann (1909) area 23	UBERON:0013554	98.30	gold quality
entorhinal cortex	UBERON:0002728	98.28	gold quality
primary visual cortex	UBERON:0002436	98.14	gold quality
prefrontal cortex	UBERON:0000451	98.09	gold quality
inferior vagus X ganglion	UBERON:0005363	98.06	gold quality
frontal cortex	UBERON:0001870	97.97	gold quality
pons	UBERON:0000988	97.86	gold quality
medial globus pallidus	UBERON:0002477	97.81	gold quality
lateral nuclear group of thalamus	UBERON:0002736	97.75	gold quality
globus pallidus	UBERON:0001875	97.74	gold quality
temporal lobe	UBERON:0001871	97.66	gold quality
dorsolateral prefrontal cortex	UBERON:0009834	97.66	gold quality
right frontal lobe	UBERON:0002810	97.60	gold quality
caudate nucleus	UBERON:0001873	97.57	gold quality
nucleus accumbens	UBERON:0001882	97.53	gold quality
putamen	UBERON:0001874	97.51	gold quality
lateral globus pallidus	UBERON:0002476	97.42	gold quality
superior vestibular nucleus	UBERON:0007227	97.37	gold quality
substantia nigra pars reticulata	UBERON:0001966	97.30	gold quality
substantia nigra pars compacta	UBERON:0001965	97.27	gold quality
ventral tegmental area	UBERON:0002691	97.23	gold quality
medulla oblongata	UBERON:0001896	97.21	gold quality
Brodmann (1909) area 9	UBERON:0013540	97.21	gold quality
C1 segment of cervical spinal cord	UBERON:0006469	97.20	gold quality

Single-cell (SCXA)

Detected in 2 experiment(s), a significant marker in 1.

Experiment	Marker?	Max mean expression
E-ANND-3	yes	4.49
E-GEOD-124858	no	1.29

Regulation

Is transcription factor: no

Upstream regulators (CollecTRI, top): MYCN

miRNA regulators (miRDB)

110 targeting PPP2R2C, top 30 by miRDB confidence (max_score; target_count = how many genes the miRNA targets in total — lower means more specific):

miRNA	Max score	Avg score	miRNA target_count
HSA-MIR-8485	100.00	77.57	4731
HSA-MIR-200B-3P	100.00	73.31	2693
HSA-MIR-200C-3P	100.00	73.35	2685
HSA-MIR-429	100.00	73.44	2698
HSA-MIR-4262	100.00	73.26	3931
HSA-MIR-3613-3P	100.00	76.36	7965
HSA-MIR-4713-3P	100.00	65.92	505
HSA-MIR-513B-5P	99.99	69.96	2150
HSA-MIR-4803	99.98	71.99	3117
HSA-MIR-302C-5P	99.97	72.56	3642
HSA-MIR-3148	99.97	75.06	6478
HSA-MIR-559	99.95	72.28	3609
HSA-MIR-548AB	99.95	71.31	3488
HSA-MIR-548A-5P	99.94	71.27	3482
HSA-MIR-548AD-5P	99.94	71.23	3502
HSA-MIR-548AE-5P	99.94	71.23	3502
HSA-MIR-548AK	99.94	71.24	3488
HSA-MIR-548AM-5P	99.94	71.24	3488
HSA-MIR-548AP-5P	99.94	71.14	3489
HSA-MIR-548AQ-5P	99.94	71.34	3426
HSA-MIR-548AR-5P	99.94	71.28	3515
HSA-MIR-548AS-5P	99.94	71.22	3482
HSA-MIR-548AU-5P	99.94	71.24	3488
HSA-MIR-548AY-5P	99.94	71.23	3502
HSA-MIR-548B-5P	99.94	71.23	3502
HSA-MIR-548BB-5P	99.94	71.27	3509
HSA-MIR-548C-5P	99.94	71.24	3488
HSA-MIR-548D-5P	99.94	71.23	3502
HSA-MIR-548H-5P	99.94	71.24	3488
HSA-MIR-548I	99.94	71.25	3481

Literature-anchored findings (GeneRIF, showing 9)

• specific PP2A complexes involved in human cell transformation (PMID:14998489)
• novel mechanism of c-SRC regulation whereby in response to stress c-SRC activity is regulated, at least in part, through loss of the interaction with its inhibitor, PR55gamma (PMID:18069897)
• encoding a subunit of proteinphosphatase 2A with a unique expression pattern in brain and a role in synaptic plasticity (PMID:20601260)
• evidence suggests that allelic variation in PPP2R2C may be associated with a variety of personality traits and ADHD per se. (PMID:22664926)
• These findings provide insights into mechanisms by which prostate cancers resist AR-pathway suppression and support inhibiting PPP2R2C complexes. (PMID:23493267)
• PPP2R2C is a potential tumor suppressor gene in human brain cancers. (PMID:24126060)
• miR-1301 promoted prostate cancer proliferation by inhibiting PPP2R2C. (PMID:27261573)
• B55gamma is induced by glucocorticoid receptor in human primary BM-MSCs during differentiation to osteoblast and is required for osteoblast morphogenesis. (PMID:28805158)
• High genetic risk scores of SLIT3, PLEKHA5 and PPP2R2C variants increase susceptibility to increased insulin resistance by 50% and its risk may be exacerbated by consuming more than 10 cups coffee/week or 220 mg caffeine/day. (PMID:30454882)

Cross-species orthologs

5 orthologs

Organism	Symbol	Gene ID
danio_rerio	ppp2r2ca	ENSDARG00000056797
danio_rerio	ppp2r2cb	ENSDARG00000062277
mus_musculus	Ppp2r2c	ENSMUSG00000029120
rattus_norvegicus	Ppp2r2c	ENSRNOG00000058202
caenorhabditis_elegans	sur-6	WBGENE00006352

Paralogs (3): PPP2R2B (ENSG00000156475), PPP2R2D (ENSG00000175470), PPP2R2A (ENSG00000221914)

Protein

Protein identifiers

Serine/threonine-protein phosphatase 2A 55 kDa regulatory subunit B gamma isoform — Q9Y2T4 (reviewed: Q9Y2T4)

Alternative names: IMYPNO1, PP2A subunit B isoform B55-gamma, PP2A subunit B isoform PR55-gamma, PP2A subunit B isoform R2-gamma, PP2A subunit B isoform gamma

All UniProt accessions (2): Q9Y2T4, D6R943

UniProt curated annotations — full annotation on UniProt →

Function. The B regulatory subunit might modulate substrate selectivity and catalytic activity, and might also direct the localization of the catalytic enzyme to a particular subcellular compartment.

Subunit / interactions. PP2A consists of a common heterodimeric core enzyme, composed of a 36 kDa catalytic subunit (subunit C) and a 65 kDa constant regulatory subunit (PR65 or subunit A), that associates with a variety of regulatory subunits. Proteins that associate with the core dimer include three families of regulatory subunits B (the R2/B/PR55/B55, R3/B’’/PR72/PR130/PR59 and R5/B’/B56 families), the 48 kDa variable regulatory subunit, viral proteins, and cell signaling molecules. Interacts with IER5.

Similarity. Belongs to the phosphatase 2A regulatory subunit B family.

Isoforms (4)

UniProt ID	Names	Canonical?
Q9Y2T4-1	1	yes
Q9Y2T4-2	2
Q9Y2T4-3	3
Q9Y2T4-4	4

RefSeq proteins (6): NP_001193923, NP_001193924, NP_001193925, NP_001350317, NP_065149, NP_870991 (=MANE)

Domains & families (InterPro)

ID	Name	Type
IPR000009	PP2A_PR55	Family
IPR001680	WD40_rpt	Repeat
IPR015943	WD40/YVTN_repeat-like_dom_sf	Homologous_superfamily
IPR018067	PP2A_PR55_CS	Conserved_site
IPR036322	WD40_repeat_dom_sf	Homologous_superfamily

UniProt features (14 total): repeat 7, splice variant 3, sequence conflict 3, chain 1

Structure

Experimental structures (PDB)

0 structures.

Predicted structure (AlphaFold)

Model	pLDDT	Fraction very-high
AF-Q9Y2T4-F1	89.53	0.75

Function

Pathways and Gene Ontology

Reactome pathways

0 pathways

MSigDB gene sets: 96 (showing top): RNGTGGGC_UNKNOWN, AP1_01, PEREZ_TP63_TARGETS, TATTATA_MIR374, KEGG_TIGHT_JUNCTION, HANN_RESISTANCE_TO_BCL2_INHIBITOR_UP, ATGTTAA_MIR302C, WANG_ESOPHAGUS_CANCER_VS_NORMAL_DN, chr4p16, TGANTCA_AP1_C, NRF2_Q4, FUJII_YBX1_TARGETS_DN, PEREZ_TP53_AND_TP63_TARGETS, HAND1E47_01, ACEVEDO_METHYLATED_IN_LIVER_CANCER_DN

GO Biological Process (0):

GO Molecular Function (2): protein phosphatase regulator activity (GO:0019888), protein binding (GO:0005515)

GO Cellular Component (2): protein phosphatase type 2A complex (GO:0000159), cytosol (GO:0005829)

GO top-level categories

Rollup of top GO terms by namespace:

Category	Terms
phosphoprotein phosphatase activity	1
phosphatase regulator activity	1
protein phosphatase binding	1
binding	1
protein serine/threonine phosphatase complex	1
cytoplasm	1
cellular anatomical structure	1

Protein interactions and networks

STRING

2004 interactions, top by confidence (×1000):

Protein A	Protein B	Partner UniProt	Score
PPP2R2C	PPP2R1B	P30154	874
PPP2R2C	PPP2R5C	Q13362	722
PPP2R2C	PPP2R3B	Q9Y5P8	719
PPP2R2C	PPP2CA	P05323	712
PPP2R2C	PPP2R3C	Q969Q6	687
PPP2R2C	PPP2R1A	P30153	678
PPP2R2C	PPP2R5A	Q15172	644
PPP2R2C	STRN	O43815	633
PPP2R2C	PPP2R5B	Q15173	612
PPP2R2C	PPP2R3A	Q06190	568
PPP2R2C	PPP2R5D	Q14738	510
PPP2R2C	MINK1	Q8N4C8	508
PPP2R2C	PPP2R5E	Q16537	495
PPP2R2C	PTPA	Q15257	491
PPP2R2C	HMX1	Q9NP08	458

IntAct

22 interactions, top by confidence:

A	B	Type	Score
PPP2R2C	PPP2R1A	psi-mi:“MI:0914”(association)	0.730
SERTAD4	PPP2R1A	psi-mi:“MI:0914”(association)	0.730
PPP2R2C	PPP2CA	psi-mi:“MI:0915”(physical association)	0.710
PPP2CA	PPP2R2C	psi-mi:“MI:0914”(association)	0.710
PPP2R2C	TCP1	psi-mi:“MI:0914”(association)	0.640
PPP2R2C	rep	psi-mi:“MI:0915”(physical association)	0.550
PPP2R2D	BAG2	psi-mi:“MI:0914”(association)	0.350
PPP2R2A	S100A8	psi-mi:“MI:0914”(association)	0.350
PPP2R2C	BAG2	psi-mi:“MI:0914”(association)	0.350
SLX4	SMAP	psi-mi:“MI:0914”(association)	0.350
M		psi-mi:“MI:0914”(association)	0.350
rep	PRDX5	psi-mi:“MI:0914”(association)	0.350
S100A2	PLEKHG3	psi-mi:“MI:0914”(association)	0.350
SMAD9	VSIG8	psi-mi:“MI:0914”(association)	0.350
ZNF114	PPP2R1B	psi-mi:“MI:0914”(association)	0.350
SERTAD2	PPP2R1B	psi-mi:“MI:0914”(association)	0.350
PABIR1	PPP2R1B	psi-mi:“MI:0914”(association)	0.350
CBLL2	COL1A1	psi-mi:“MI:0914”(association)	0.350
PPP2R2C	PLEKHG3	psi-mi:“MI:0914”(association)	0.350
	PPP2R1A	psi-mi:“MI:0914”(association)	0.350

BioGRID (177): CCT3 (Affinity Capture-MS), CCT6A (Affinity Capture-MS), CCT2 (Affinity Capture-MS), CCT7 (Affinity Capture-MS), POLR3A (Affinity Capture-MS), SIK2 (Affinity Capture-MS), TCP1 (Affinity Capture-MS), IQGAP1 (Affinity Capture-MS), PPP2R1B (Affinity Capture-MS), PPP2R1A (Affinity Capture-MS), STRN (Affinity Capture-MS), STRN3 (Affinity Capture-MS), STRN4 (Affinity Capture-MS), PPP2R2B (Affinity Capture-MS), ZCCHC8 (Affinity Capture-MS)

ESM2 similar proteins: A1L3L9, A2X2K3, B0R0D7, B6VA23, O35142, O55029, P35606, P36876, P36877, P50410, P54614, P56932, P63150, P63151, P97888, Q00005, Q00006, Q0D2F4, Q0E2P1, Q29090, Q38821, Q39247, Q4R4I8, Q4R7Z4, Q4R8L3, Q5E9Q7, Q5R4A2, Q5R664, Q5Z8Z7, Q5ZIY5, Q66LE6, Q6AY57, Q6DIY3, Q6NY64, Q6P1F6, Q6QEF8, Q6ZWR4, Q7ZWU5, Q7ZX64, Q80W47

Diamond homologs: A1L3L9, A2X2K3, B6VA23, G5EDR3, P36872, P36876, P36877, P50410, P53031, P54614, P56932, P63150, P63151, P97888, Q00005, Q00006, Q00362, Q0D2F4, Q0E2P1, Q12702, Q29090, Q38821, Q39247, Q4R7Z4, Q4R8L3, Q54Q99, Q5E9Q7, Q5R4A2, Q5Z8Z7, Q5ZIY5, Q66LE6, Q6DIY3, Q6NY64, Q6P1F6, Q6ZWR4, Q7ZX64, Q8BG02, Q925E7, Q95LP0, Q9Y2T4

SIGNOR signaling

1 interactions.

A	Effect	B	Mechanism
PPP2R2C	“down-regulates activity”	SRC	binding

Disease & clinical

Clinical variants and AI predictions

ClinVar

53 variants total. Per-class counts are floors (≥ shown; pagination cap):

Classification	Count (floor)
Pathogenic	0
Likely pathogenic	0
Uncertain significance	39
Likely benign	0
Benign	2

Top pathogenic / likely-pathogenic (0)

SpliceAI

2546 predictions. Top by Δscore:

Variant	Effect	Δscore
4:6323589:TGACG:T	acceptor_gain	1.0000
4:6323592:CG:C	acceptor_gain	1.0000
4:6323594:C:CC	acceptor_gain	1.0000
4:6329256:GCTTA:G	donor_loss	1.0000
4:6329257:CTTA:C	donor_loss	1.0000
4:6329258:TTACC:T	donor_loss	1.0000
4:6329259:TAC:T	donor_loss	1.0000
4:6329260:A:AC	donor_gain	1.0000
4:6329260:A:C	donor_loss	1.0000
4:6329261:C:CC	donor_gain	1.0000
4:6333727:AAAGA:A	acceptor_gain	1.0000
4:6333728:AAGA:A	acceptor_gain	1.0000
4:6333729:AGA:A	acceptor_gain	1.0000
4:6333729:AGAC:A	acceptor_loss	1.0000
4:6333730:GA:G	acceptor_gain	1.0000
4:6333731:AC:A	acceptor_loss	1.0000
4:6333732:C:CC	acceptor_gain	1.0000
4:6333733:T:C	acceptor_loss	1.0000
4:6347844:A:AC	donor_gain	1.0000
4:6347844:ACG:A	donor_gain	1.0000
4:6347845:C:CC	donor_gain	1.0000
4:6347845:CG:C	donor_gain	1.0000
4:6347845:CGC:C	donor_gain	1.0000
4:6372521:A:AC	donor_gain	1.0000
4:6372522:C:CC	donor_gain	1.0000
4:6372525:AAGCT:A	donor_gain	1.0000
4:6372529:T:TA	donor_gain	1.0000
4:6375817:A:AT	donor_loss	1.0000
4:6375818:CCTG:C	donor_gain	1.0000
4:6375927:TTTAT:T	acceptor_gain	1.0000

AlphaMissense

3019 scored. Top likely-pathogenic:

Variant	Protein change	am_pathogenicity
4:6323342:A:G	L435P	1.000
4:6323357:G:T	A430D	1.000
4:6323363:G:T	A428D	1.000
4:6323388:A:G	W420R	1.000
4:6323388:A:T	W420R	1.000
4:6323516:G:T	A377D	1.000
4:6323574:A:C	Y358D	1.000
4:6323574:A:G	Y358H	1.000
4:6323579:C:A	G356V	1.000
4:6323579:C:T	G356E	1.000
4:6323580:C:A	G356W	1.000
4:6323580:C:G	G356R	1.000
4:6323580:C:T	G356R	1.000
4:6329288:A:C	F342L	1.000
4:6329288:A:T	F342L	1.000
4:6329290:A:G	F342L	1.000
4:6329295:T:A	D340V	1.000
4:6329296:C:G	D340H	1.000
4:6329297:G:C	F339L	1.000
4:6329297:G:T	F339L	1.000
4:6329298:A:C	F339C	1.000
4:6329298:A:G	F339S	1.000
4:6329299:A:C	F339V	1.000
4:6329299:A:G	F339L	1.000
4:6329299:A:T	F339I	1.000
4:6329301:A:T	I338N	1.000
4:6329307:T:A	D336V	1.000
4:6329308:C:G	D336H	1.000
4:6329317:A:G	Y333H	1.000
4:6329319:A:G	L332P	1.000

dbSNP variants (sampled 300 via entrez): RS10000024 (4:6423539 A>G), RS1000014818 (4:6470834 G>A), RS1000020151 (4:6371575 T>C), RS1000023460 (4:6461736 T>C), RS1000055518 (4:6357437 C>A,T), RS1000065825 (4:6549586 C>G,T), RS1000073588 (4:6499537 A>T), RS1000096133 (4:6535455 C>A,T), RS1000119446 (4:6408430 G>C), RS10001231 (4:6332552 C>G,T), RS1000124714 (4:6363653 G>A), RS1000130401 (4:6541776 C>G), RS1000139383 (4:6408245 C>T), RS10001583 (4:6523803 T>A,C,G), RS1000167815 (4:6516242 G>A)

Disease associations

OMIM: gene MIM:605997 | disease phenotypes:

GenCC curated gene-disease

Mondo (0):

Orphanet (0):

HPO phenotypes

0 total (0 of 0 shown, HPO-id order):

GWAS associations

5 associations (top):

Study	Trait	p-value
GCST000478_2	Type 2 diabetes	1.000000e-08
GCST002709_27	Electroencephalogram traits	9.000000e-06
GCST004134_15	Multiple keratinocyte cancers	5.000000e-06
GCST008513_7	Health literacy	2.000000e-06
GCST009391_1718	Metabolite levels	7.000000e-06

EFO canonical traits (3, from GWAS)

EFO ID	Trait name
EFO:0004357	electroencephalogram measurement
EFO:0010104	health literacy measurement
EFO:0010341	cholesteryl ester 16:0 measurement

Drugs & pharmacology

Drug and pharmacology data

Is drug target: no

PharmGKB: 1 entry (VIP=true, CPIC=false)

CTD chemical–gene interactions

56 total (human), top 30 by PubMed support.

Chemical	Actions (top 5)	PubMed papers
Valproic Acid	affects cotreatment, increases expression, affects expression, increases methylation	9
sodium arsenite	decreases expression, increases abundance, increases expression	5
Estradiol	affects cotreatment, increases expression	3
bisphenol A	affects cotreatment, decreases methylation, increases expression	2
entinostat	increases expression, affects cotreatment	2
Benzo(a)pyrene	affects methylation, increases methylation	2
Copper	affects binding, increases expression, affects cotreatment, decreases expression	2
Aflatoxin B1	increases methylation	2
aristolochic acid I	decreases expression	1
OTX015	decreases expression	1
bisphenol F	affects cotreatment, increases methylation	1
mivebresib	decreases expression	1
dicrotophos	increases expression	1
methylmercuric chloride	increases expression	1
testosterone undecanoate	affects cotreatment, increases expression	1
trichostatin A	increases expression	1
arsenite	decreases expression, increases abundance	1
11-nor-delta(9)-tetrahydrocannabinol-9-carboxylic acid	affects methylation, increases abundance	1
benzo(e)pyrene	increases methylation	1
aflatoxin B2	affects methylation	1
cupric chloride	increases expression	1
beta-methylcholine	affects expression	1
2,4-decadienal	affects response to substance	1
CGP 52608	affects binding, increases reaction	1
4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide	affects cotreatment, increases expression	1
erucylphospho-N,N,N-trimethylpropylammonium	increases expression	1
abrine	decreases expression	1
dorsomorphin	affects cotreatment, increases expression	1
bisphenol S	affects methylation	1
apatinib	affects cotreatment, increases expression	1

Cellosaurus cell lines

1 cell lines: 1 cancer cell line

First 10 cell lines (id-ordered, not curated):

Cellosaurus	Name	Category	Sex
CVCL_TF97	HAP1 PPP2R2C (-)	Cancer cell line	Male

Clinical trials (associated diseases)

0 trials via MONDO — disease-level, not drug-specific.